醋酸乌利司他治疗子宫平滑肌瘤的健康相关生活质量:一项随机对照试验
两项3期多中心双盲安慰剂对照试验(VENUS I和II)纳入589例子宫平滑肌瘤伴异常子宫出血女性,随机接受醋酸乌利司他5mg、10mg或安慰剂。汇总分析显示两种剂量在子宫肌瘤症状健康相关生活质量量表所有维度较基线的改善均显著优于安慰剂(P<.001)。
要点
- 醋酸乌利司他5mg和10mg组在子宫肌瘤症状健康相关生活质量量表所有维度较基线的改善均显著优于安慰剂(P<.001)。
- 修订活动量表达到有意义变化的患者比例:安慰剂组34.9%,5mg组73.5%(OR 5.0),10mg组80.6%(OR 7.9)。
- VENUS II中第2疗程两种剂量仍维持获益,从安慰剂转换为乌利司他后也出现改善。
核心结论
- 对有症状子宫平滑肌瘤女性,醋酸乌利司他与安慰剂相比,健康相关生活质量和症状严重程度均有显著改善。
研究设计与样本
- 两项3期、多中心、双盲、安慰剂对照随机试验(VENUS I和II),女性随机接受醋酸乌利司他5mg、10mg或安慰剂。
- 汇总意向性治疗人群共589例(安慰剂169例,乌利司他5mg 215例,乌利司他10mg 205例)。
- 使用子宫肌瘤症状健康相关生活质量问卷在基线及1个(VENUS I和II)和2个(VENUS II)12周疗程结束时评估。
主要发现
- 汇总分析中,两种乌利司他剂量在子宫肌瘤症状健康相关生活质量量表所有维度较基线的改善均显著大于安慰剂(P<.001)。
- 修订活动量表达到有意义变化(30分或以上)的患者:安慰剂组51例(34.9%),乌利司他5mg组144例(73.5%;OR 5.0 [97.5%CI 2.9-8.6]),乌利司他10mg组141例(80.6%;OR 7.9 [97.5%CI 4.3-14.6])。
- VENUS II中第1和第2疗程结束时,两种乌利司他剂量在所有子宫肌瘤症状健康相关生活质量量表上较基线的改善均显著优于安慰剂(P<.01)。
- 修订活动量表平均评分显示乌利司他的获益在第2疗程得以维持,从安慰剂转换为乌利司他后出现改善;其他量表结果相似。
关键数值与推荐
- 症状严重程度量表有意义变化定义为20分或以上。
- 健康相关生活质量总量表有意义变化定义为20分或以上。
- 修订活动量表有意义变化定义为30分或以上。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To investigate effects of ulipristal acetate on health-related quality of life (QOL) and symptom severity in women with symptomatic uterine leiomyomas and abnormal uterine bleeding. METHODS: Women were randomized to ulipristal (5 mg, 10 mg) or placebo in two phase 3, multicenter, double-blind, placebo-controlled trials (VENUS I and II). Health-related QOL and symptom severity were assessed at baseline, and over one (VENUS I and II) and two (VENUS II) 12-week treatment courses using the Uterine Fibroid Symptom Health-Related Quality of Life questionnaire. In pooled VENUS I and II data, change from baseline to the end of the first course for each Uterine Fibroid Symptom Health-Related Quality of Life scale was analyzed, including a Revised Activities subscale that measured physical and social activities. The proportion of women achieving meaningful change in the Symptom Severity (20 or more points), Health-Related QOL Total (20 or more points), and Revised Activities (30 or more points) scales was calculated. In VENUS II data, change from baseline to the end of each course in each scale was analyzed for each treatment arm. RESULTS: In pooled analyses, the intent-to-treat population included 589 patients (placebo, n=169; ulipristal 5 mg, n=215; ulipristal 10 mg, n=205). Significantly greater improvements from baseline in all Uterine Fibroid Symptom Health-Related Quality of Life scales were observed with both ulipristal doses compared with placebo (P<.001). A meaningful change in Revised Activities was achieved by 51 patients receiving placebo (34.9%), compared with 144 (73.5%; OR 5.0 [97.5% CI 2.9-8.6]) and 141 (80.6%; OR 7.9 [97.5% CI 4.3-14.6]) patients receiving ulipristal 5 mg, and 10 mg, respectively. In VENUS II, at end of courses 1 and 2, both ulipristal doses demonstrated significant improvements from baseline compared with placebo for all Uterine Fibroid Symptom Health-Related Quality of Life scales (P<.01). Mean Revised Activities scores showed that beneficial ulipristal effects were maintained in course 2, and improvements occurred on switching to ulipristal; results for other scales were similar. CONCLUSION: Ulipristal was associated with significant improvements in health-related QOL and symptom severity compared with placebo for women with symptomatic uterine leiomyomas. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov, NCT02147197 and NCT02147158. FUNDING SOURCE: Allergan plc, Dublin, Ireland.
引用
- Lukes AS, Soper D, Harrington A, et al. Health-Related Quality of Life With Ulipristal Acetate for Treatment of Uterine Leiomyomas: A Randomized Controlled Trial. Obstet Gynecol. 2019. PMID: 30969201. doi:10.1097/AOG.0000000000003211
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。